Clinical and Economic Burden of Hepatic and Extrahepatic Complications from Chronic Hepatitis C: A Retrospective Analysis of German Sickness Fund Data

Kraus, Michael R.; Kleine, H. O.; Thönnes, Stefanie; Pignot, M; González, Yuri Sánchez

doi:10.1007/s40121-018-0204-3

Cited by 3 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatitis C has been one of those lethal types of the virus which slowly and gradually disrupts the architecture of liver and eventually fails the functioning capacity of this organ. Chronic liver disease and cirrhotic liver is one of the main complications of untreated HCV infection, HCC is another 18 . Level of suspicion is usually high among the physicians when the disease is advanced and untreated.…”

Section: Discussionmentioning

confidence: 99%

Frequency of Hepatocellular Carcinoma and Associated Sociodemographic Factors in Treated Patients of Chronic Hepatitis C

Tariq

Abbas

Saeed

et al. 2021

PAFMJ

View full text Add to dashboard Cite

Objective: To look for frequency and associated socio-demographic factors of newly diagnosed patients of heaptocellular carcinoma (HCC) among patients treated adequately for hepatitis C infection. Study Design: Correlational study. Place and Duration of Study: Gastroenterology Department, Pak Emirates Military Hospital Rawalpindi, fromNov 2017 to Oct 2018. Methodology: This analysis was performed on 170 patients treated effectively for hepatitis C with standard antiviral therapy at our hospital. They were followed up for two years after the sustained viral response has been achieved. Ultrasonography was done in all cases and contrast enhanced computerized tomography scan done on patients who were positive on ultrasound. Factors like age, gender, genotype of heaptocellular carcinoma, presence of cirrhosis and model for end-stage liver disease (MELD) score were related with presence of heaptocellular carcinoma among the target population. Results: Out of 170 patients included in final analysis 121 were male, 49 were female. About 53 patients werediagnosed as suffering from heaptocellular carcinoma while 117 were negative for that. Thirty six patients hadcirrhosis while 134 non cirrhotic. After applying the binary logistic regression genotypes other than 3, high model for end-stage liver disease score & presence of cirrhosis had a strong relationship with presence of heaptocellular carcinoma among the patients treated for hepatitis C virus. Conclusion: Physicians and patients cannot ignore the possibility of a malignant outcome even after successfultreatment of hepatitis C. Local protocols should be set for screening especially the high risk cases even aftertreatment of hepatitis..........

show abstract

Section: Discussionmentioning

confidence: 99%

Frequency of Hepatocellular Carcinoma and Associated Sociodemographic Factors in Treated Patients of Chronic Hepatitis C

Tariq

Abbas

Saeed

et al. 2021

PAFMJ

View full text Add to dashboard Cite

show abstract

“…Similar data were used in a study assessing the clinical and economic burden of hepatic and EHCs associated with CHC in Germany [ 25 ]. In that study, CHC was associated with a substantial burden (e.g., medical costs) largely due to hepatic complications and EHCs, subject to limitations similar to those of the present study [ 25 ].…”

Section: Methodsmentioning

confidence: 99%

Improvement of Hepatic and Extrahepatic Complications from Chronic Hepatitis C After Antiviral Treatment: A Retrospective Analysis of German Sickness Fund Data

et al. 2018

Self Cite

View full text Add to dashboard Cite

IntroductionGerman data regarding the economic burden of chronic hepatitis C (CHC) and potential benefits of CHC treatment are limited. To address this issue, we evaluated the role of treatment in mitigating the economic burden of hepatic and extrahepatic complications (EHCs) from CHC virus infection in Germany.MethodsThis retrospective, cross-sectional study used claims data from the Betriebskrankenkasse German sickness fund (2007–2014) to assess the medical costs of hepatic complications and EHCs, including conditions that are prevalent and behavioral factors associated with CHC. All-cause costs, medical costs related to hepatic and EHCs, and CHC-related and non-CHC-related pharmacy costs (adjusted to the 2016 euro rate) were calculated and compared between CHC patients’ treated (n = 1714) and untreated time (n = 7124) and CHC patients that initiated treatment early (i.e., without cirrhosis; n = 1552) vs. late (i.e., with cirrhosis; n = 162).ResultsCHC treatment was associated with an average adjusted savings of €1885 in annual all-cause medical costs per patient, with a significant proportion attributed to EHC-related cost savings (adjusted difference, €1363; P < 0.01). Although initiating CHC treatment early was economically beneficial compared with initiating treatment late, the total cost savings were not significantly different (annual average adjusted difference, €3831; P = 0.27). However, nearly 60% of these savings were EHC related (adjusted difference, €2255; P < 0.01).ConclusionCHC is associated with a significant economic burden in Germany, largely due to EHCs. Antiviral treatment may reduce the burden of CHC and result in significant cost savings, even when initiated at earlier stages of liver disease.FundingAbbVie Inc.

show abstract

The role of insurance providers in supporting treatment and management of hepatitis C patients

Behzadifar

Gorji

Rezapour

et al. 2019

BMC Health Serv Res

View full text Add to dashboard Cite

Today, one of the most important global public health challenges is represented by hepatitis C virus (HCV), which imposes relevant costs. Globally speaking, the median cost of HCV-related complications ranges from $280 for an uncomplicated hepatitis to $139,070 for a liver transplantation. There are effective therapies for HCV patients worldwide, which has increased the hope of improving the process of managing and curing these patients. The adherence of patients to the pharmacological treatment and the use of effective drugs in the management of HCV disease are of crucial importance for health policy- and decision-makers. Studies show that, globally, insurance coverage for patients with HCV is not adequate in that still many patients are not covered by insurance programs. This issue as well as the economic conditions of countries are very serious challenges for ensuring an effective treatment. The most important and greatest help currently available to ensure HCV treatment is to implement plans to reduce costs and support patients. Some studies have shown that the expansion of coverage by private payers seems able to generate positive spillover benefits to public insures. Insurers, in addition to maintaining and increasing their own interests, are trying to increase their social status as a sponsor of patients. In conclusion, HCV disease requires serious policies and affordable insurance coverage.

show abstract

Clinical and Economic Burden of Hepatic and Extrahepatic Complications from Chronic Hepatitis C: A Retrospective Analysis of German Sickness Fund Data

Cited by 3 publications

References 23 publications

Frequency of Hepatocellular Carcinoma and Associated Sociodemographic Factors in Treated Patients of Chronic Hepatitis C

Frequency of Hepatocellular Carcinoma and Associated Sociodemographic Factors in Treated Patients of Chronic Hepatitis C

Improvement of Hepatic and Extrahepatic Complications from Chronic Hepatitis C After Antiviral Treatment: A Retrospective Analysis of German Sickness Fund Data

The role of insurance providers in supporting treatment and management of hepatitis C patients

Contact Info

Product

Resources

About